Methods
To identify potential clinically significant life-threatening DDIs, this
study used the U.S. Food and Drug Administration (FDA) prescribing table
of LPV/RTV enlisted
contraindicated medications 9. Likely, potential
clinically significant
life-threatening DDIs were also
identified from the lists of contraindicated drugs of LPV/RTV as
provided by the Liverpool COVID-19 drug interaction resource10. The interacting contraindicated drugs were
putatively paired with LPV/RTV called severe DDI pairs predicted to
cause life-threatening ADRs.
The severe DDI pairs identified from the FDA and Liverpool COVID-19
interaction resources were then analyzed using a Venn diagram showing
the unique or overlapping drug pairs between these two well recognized
evidence-based international DDI resources.